Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

IMPORTANCE: Guidelines currently recommend ticagrelor over clopidogrel for patients with acute coronary syndrome (ACS) based on randomized clinical trial data in which ticagrelor reduced major adverse coronary events (MACE) vs clopidogrel but increased bleeding and dyspnea. OBJECTIVE: To compare the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Intern Med
Autors principals: Turgeon, Ricky D., Koshman, Sheri L., Youngson, Erik, Har, Bryan, Wilton, Stephen B., James, Matthew T., Graham, Michelle M.
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2020
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6990835/
https://ncbi.nlm.nih.gov/pubmed/31930361
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamainternmed.2019.6447
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars